Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$3.7 million.

  • Capricor Therapeutics' Net Cash Flow fell 10646.71% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.9 million, marking a year-over-year decrease of 18227.78%. This contributed to the annual value of -$3.4 million for FY2024, which is 16693.08% down from last year.
  • Capricor Therapeutics' Net Cash Flow amounted to -$3.7 million in Q3 2025, which was down 10646.71% from -$5.6 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Net Cash Flow ranged from a high of $57.7 million in Q3 2024 and a low of -$57.1 million during Q4 2024
  • For the 5-year period, Capricor Therapeutics' Net Cash Flow averaged around -$692394.3, with its median value being -$768395.0 (2023).
  • The largest annual percentage gain for Capricor Therapeutics' Net Cash Flow in the last 5 years was 686731.26% (2024), contrasted with its biggest fall of 109979.87% (2024).
  • Over the past 5 years, Capricor Therapeutics' Net Cash Flow (Quarter) stood at -$6.0 million in 2021, then surged by 119.98% to $1.2 million in 2022, then soared by 380.01% to $5.7 million in 2023, then plummeted by 1099.8% to -$57.1 million in 2024, then skyrocketed by 93.47% to -$3.7 million in 2025.
  • Its Net Cash Flow stands at -$3.7 million for Q3 2025, versus -$5.6 million for Q2 2025 and $17.5 million for Q1 2025.